A naukri.com initiative
Bioengineer
5d
122
Image Credit: Bioengineer
Breakthrough Therapy Offers Hope Against Treatment-Resistant Skin Cancers
- A groundbreaking discovery in cancer immunotherapy sheds light on immune checkpoint blockade (ICB) therapy resistance, offering promising solutions.
- Research led by Dr. Shoba Amarnath at Newcastle University reveals mechanisms behind ICB therapy failure in metastatic skin cancers.
- The study, to be published in Nature Immunology, proposes a novel combination strategy to enhance immunotherapy efficacy.
- Immune checkpoint blockade targets PD-1 to activate T cells against cancer, but over 60% of patients do not benefit from this therapy.
- The study focuses on the role of regulatory T cells (Tregs) in tumor resistance to ICB, uncovering a paradoxical effect of PD-1 inhibition.
- By targeting CD30, an emerging immunosuppressive axis in solid tumors, researchers reversed resistance and suppressed melanoma growth in preclinical models.
- A Phase II trial combining anti-PD1 ICB with anti-CD30 therapy showed a 24% survival advantage in refractory metastatic melanoma patients.
- The research's implications extend to various solid tumors, offering a promising approach to overcoming immune evasion in cancer.
- Insights into Treg behavior in ICB resistance and identification of targetable molecules aim to broaden clinical responses and reduce treatment resistance.
- Newcastle University's research, supported by prestigious bodies, aims to optimize cancer immunotherapy outcomes through innovative solutions.
Read Full Article
7 Likes
For uninterrupted reading, download the app